CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia
Open accessAbstract
CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Among cancers, AML and CML are the only types in which CIP2A mRNA appears lower than in corresponding normal tissue.
“This is interesting, as AML and CML are the only cancer types in which CIP2A seems to be underexpressed at the mRNA level compared with corresponding normal tissue (Fig. 6I; refs.4,23).”
From Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias (2021) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Bennett, J. M., Catovsky, D., Mt, D., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,595 · see citing works
Vardiman, J., Thiele, J., Arber, D., Brunning, R., Borowitz, M., Porwit, A., Harris, N., Beau, M. L. L., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,837 · see citing works
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628 · see citing works
Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications
Marcucci, G., Haferlach, T., & Döhner, H. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2554 · Cited by 573 · see citing works
Protein phosphatase 2A: a target for anticancer therapy
Perrotti, D., & Neviani, P. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70558-2 · Cited by 400 · see citing works
CIP2A Is Associated with Human Breast Cancer Aggressivity
Côme, C., Laine, A., Chanrion, M., Edgren, H., Mattila, E., Liu, X., Jonkers, J., Ivaska, J., Isola, J., Darbon, J.-M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3283 · Cited by 221 · see citing works
Luo, H., Li, Q., O’Neal, J., Kreisel, F. H. C., Beau, M. M. L., & Tomasson, M. H. (2005) · Blood · doi:10.1182/blood-2005-02-0734 · Cited by 177 · see citing works
Khanna, A., Pimanda, J. E., & Westermarck, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1994 · Cited by 154 · see citing works
Cristóbal, I., García-Ortí, L., Cirauqui, C., Alonso, M. M., Calasanz, M. J., & Odero, M. D. (2011) · Leukemia · doi:10.1038/leu.2010.294 · Cited by 138 · see citing works
Self-citationLaine, A., Sihto, H., Come, C., Rosenfeldt, M. T., Zwolinska, A., Niemelä, M., Khanna, A., Chan, E. K., Kähäri, V.-M., Kellokumpu-Lehtinen, P.-L., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0292 · Cited by 130 · see citing works
Cristóbal, I., García-Ortí, L., Cirauqui, C., Cortés-Lavaud, X., Garcı́a-Sánchez, A., Calasanz, M. J., & Odero, M. D. (2011) · Haematologica · doi:10.3324/haematol.2011.050542 · Cited by 123 · see citing works
Self-citationAgarwal, A., MacKenzie, R. J., Pippa, R., Eide, C. A., Oddo, J., Tyner, J. W., Sears, R. C., Vitek, M. P., Odero, M. D., Christensen, D. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2575 · Cited by 123 · see citing works
Self-citationTreatment of acute myeloid leukemia: are we making progress?
Burnett, A. K. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.1.3797038 · Cited by 89 · see citing works
Pippa, R., Dominguez, A., Christensen, D. J., Moreno–Miralles, I., Blanco‐Prieto, M. J., Vitek, M. P., & Odero, M. D. (2014) · Leukemia · doi:10.1038/leu.2014.141 · Cited by 71 · see citing works
Self-citationWang, J., LI, W., Li, L., Yu, X., Jia, J., & Chen, C. (2011) · International Journal of Laboratory Hematology · doi:10.1111/j.1751-553x.2010.01288.x · Cited by 67 · see citing works
Treatment of acute myeloid leukemia: are we making progress?
Burnett, A. K. (2012) · PubMed · doi:10.1182/asheducation-2012.1.1 · Cited by 38 · see citing works
How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia?
Patel, J. P., & Levine, R. L. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.28.3797923 · Cited by 35 · see citing works
How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia?
Patel, J. L., & Levine, R. L. (2012) · PubMed · doi:10.1182/asheducation-2012.1.28 · Cited by 13 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Ruvolo, P. P. (2016) · BBA Clinical · doi:10.1016/j.bbacli.2016.08.002 · Cited by 143 · see citing works
Mäkelä, E., Pavic, K., Varila, T., Salmenniemi, U., Löyttyniemi, E., Nagelli, S. G., Ammunét, T., Kähäri, V.-M., Clark, R. E., Elo, L. L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3679 · Cited by 18 · see citing works
- Authors
- Barragan, E., Chillon, M. C., Castello-Cros, R., Marcotegui, N., Prieto, M. I., Hoyos, M., Pippa, R., Llop, M., Etxabe, A., Cervera, J., Rodriguez, G., Buno, I., Rifon, J., Sierra, J., Gonzalez, M., Calasanz, M. J., Sanz, M. A., & Odero, M. D.
- Affiliations
- Centro de Investigación Médica Aplicada (ES)
- Universidad de Salamanca (ES)
- Hospital de Sant Pau (ES)
- Hospital Universitari i Politècnic La Fe (ES)
- Venue
- Haematologica
- Published
- 2015-01-30
- Volume
- 100
- Issue
- 5
- Pages
- e183-e185
- ISSN
- 0390-6078 (ISSN-L)
- 1592-8721
- PMC
- PMC4420227
- OpenAlex
- W2161135181
- Cited by
- 22
- References
- 18
- Citations by year
- 2023: 4 · 2022: 1 · 2021: 4 · 2020: 3 · 2019: 4 · 2018: 1 · 2017: 2 · 2016: 3
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Haematologica (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Fundación Científica Asociación Española Contra el Cáncer
- Universidad de Navarra
- Ministerio de Ciencia e Innovación
- Gobierno de Navarra
- Instituto de Salud Carlos III (PI13/01640, PI11/, RD12/0036/0014, RD12/0036/0063, RD12/0036/0069)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Pathology and Forensic Medicine › Cancer Mechanisms and Therapy
- Keywords
- CIP2A, acute myeloid leukemia, normal karyotype, prognostic factors, gene expression, poor prognosis
- MeSH terms
- Autoantigens, Humans, Membrane Proteins, Prognosis, Leukemia, Myeloid, Acute, Gene Expression, Survival Analysis, Intracellular Signaling Peptides and Proteins, Karyotype
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
